UBS Group’s Psyence Biomedical PBM Stock Holding History

UBS Group’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-161	Closed	-$758	–	11284
2025 Q4	$758	Buy	+161	New	+$2.4K	﹤0.01%	9824
2025 Q3	–	Sell	-313	Closed	-$10.4K	–	11046
2025 Q2	$10.4K	Sell	313 -361	-54%	-$9.99K	﹤0.01%	8840
2025 Q1	$20.1K	Buy	674 +419	+164%	+$26.7K	﹤0.01%	8236
2024 Q4	$26.8K	Buy	255 +251	+6,275%	+$59.8K	﹤0.01%	7686
2024 Q3	$1.5K	Sell	4 -2	-33%	-$2.71K	﹤0.01%	8621
2024 Q2	$6.87K	Buy	6 +5	+500%	+$15K	﹤0.01%	7882
2024 Q1	$2.69K	Buy	+1	New	+$4.17K	﹤0.01%	7846

Other funds holding PBM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

UBS Group's PBM Position: Q1 2026 in Review

UBS Group sold out of Psyence Biomedical (PBM) in Q1 2026, closing a stake of 161 shares — an estimated $758 sold.

UBS Group first reported a position in PBM in Q1 2024 and held it in 7 quarters. The position peaked at $26.8K in Q4 2024. 2 funds tracked by Wall St. Rank hold PBM as of Q1 2026.

UBS Group reported no remaining Psyence Biomedical position as of Q1 2026 after selling out during the quarter.
UBS Group sold 161 Psyence Biomedical shares in Q1 2026, an estimated $758.
UBS Group first reported a position in Psyence Biomedical in Q1 2024 and held it in 7 quarters.
UBS Group's Psyence Biomedical position peaked at $26.8K in Q4 2024.
2 funds tracked by Wall St. Rank held Psyence Biomedical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.